For me – I’m a neuro-oncologist – I think that it’s been interesting. I have obviously an interest in CNS lymphoma and it’s been interesting to hear how some of the new molecular classifications and some of the nuances that pertain to systemic lymphoma also have implications for CNS lymphoma.
For example, using interferon-alpha to treat certain types of lymphoproliferative situations and that’s been interesting...
For me – I’m a neuro-oncologist – I think that it’s been interesting. I have obviously an interest in CNS lymphoma and it’s been interesting to hear how some of the new molecular classifications and some of the nuances that pertain to systemic lymphoma also have implications for CNS lymphoma.
For example, using interferon-alpha to treat certain types of lymphoproliferative situations and that’s been interesting. And also, we do see patients with systemic lymphoma, both that developed neurologic toxicity from therapies and also who have a CNS metastasis, so, it’s been a great refresher and a great conference; I’ve learned a lot.